Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Product Safety”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableAvailableNCT02397863
What this trial is testing

Epidiolex and Drug Resistant Epilepsy in Children

Who this might be right for
Epilepsy
Augusta University
Testing effectiveness (Phase 2)Active Not RecruitingNCT02637687
What this trial is testing

Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 154
Testing effectiveness (Phase 2)Study completedNCT05455112
What this trial is testing

Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis

Who this might be right for
Tuberculosis, Pulmonary
Archivel Farma S.L. 41
Early research (Phase 1)Study completedNCT05732428
What this trial is testing

Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China

Who this might be right for
Breast Cancer
Pfizer 9
Testing effectiveness (Phase 2)Looking for participantsNCT03480971
What this trial is testing

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Who this might be right for
MucositisNephrotoxicityOtotoxicity
Matrix Biomed, Inc. 120
Large-scale testing (Phase 3)Not Yet RecruitingNCT07270432
What this trial is testing

Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia

Who this might be right for
Prostatic Hyperplasia, Benign
Ache Laboratorios Farmaceuticos S.A. 218
Testing effectiveness (Phase 2)Ended earlyNCT05608187
What this trial is testing

Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers

Who this might be right for
Wound HealWound Healing Disturbance ofWound Healing Disorder+3 more
Ilya Pharma 1
Testing effectiveness (Phase 2)WithdrawnNCT01304628
What this trial is testing

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

Who this might be right for
Asthma
Palatin Technologies, Inc
Early research (Phase 1)Study completedNCT00006207
What this trial is testing

Safety and Tolerability of the Vaginal Gel PRO 2000/5

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 60
Early research (Phase 1)UnknownNCT05276609
What this trial is testing

ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Shanghai Hansoh Biomedical Co., Ltd 177
Large-scale testing (Phase 3)Study completedNCT02333799
What this trial is testing

Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB

Who this might be right for
Pulmonary Tuberculosis
Global Alliance for TB Drug Development 109
Testing effectiveness (Phase 2)Ended earlyNCT00543712
What this trial is testing

PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

Who this might be right for
Chondrosarcoma
Genentech, Inc. 15
Testing effectiveness (Phase 2)Study completedNCT04789200
What this trial is testing

Phase 2 Study of NX9 for Delineation of Bowel Anatomy

Who this might be right for
GI CarcinomaGI Disorders
Nextrast, Inc. 32
Testing effectiveness (Phase 2)Study completedNCT01765244
What this trial is testing

Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractory to Conventional (Ophthalmic) Treatment

Who this might be right for
Severe Trophic Corneal Ulcers Refractory to Conventional TreatmentSequelae of Previous Trophic Corneal Ulcers
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud 16
Large-scale testing (Phase 3)Study completedNCT06742957
What this trial is testing

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

Who this might be right for
Plaque Type Psorisis
Teva Pharmaceuticals USA 560
Large-scale testing (Phase 3)Study completedNCT00092781
What this trial is testing

MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)

Who this might be right for
Osteoarthritis
Organon and Co 500
Large-scale testing (Phase 3)Study completedNCT01309828
What this trial is testing

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Who this might be right for
Safety
Takeda 153
Not applicableStudy completedNCT03676400
What this trial is testing

Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia

Who this might be right for
Androgenic Alopecia
Medipost Co Ltd. 84
Early research (Phase 1)Study completedNCT04493671
What this trial is testing

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Who this might be right for
Pulmonary DiseaseTuberculosis, PulmonaryTuberculosis+4 more
Global Alliance for TB Drug Development 137
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Next Page